Bria-OTS (cancer immunotherapy)

2026: Product Announcement

On January 13, 2026, BriaCell Therapeutics reported a complete and persistent disappearance of lung metastases in a patient who underwent a course of personalized next-generation immunotherapy Bria-OTS. A positive result was recorded two months after the treatment.

Instead of manipulating a person's own cells, Bria-OTS therapy involves the use of pre-produced cells that correspond to a patient's HLA type - a key component of the immune system responsible for recognizing threats and triggering an immune response. Using HLA matching as a personalization mechanism, Bria-OTS provides an individual immune response. Bria-OTS therapy is based on saliva analysis, making it faster and more accessible compared to other personalized immunotherapy therapies.

𝓲

Фото: BriaCell Therapeutics

The first patient to receive Bria-OTS treatment was a 78-year-old woman with advanced metastatic breast cancer. Treatment attempts using conventional approaches did not yield results. Moreover, the woman had progression of the disease after several courses of treatment.

However, after four injections of Bria-OTS, a complete (100%) disappearance of metastases in the lungs was noted. The effect initially observed at 2 months after therapy was subsequently confirmed at 4 months, 6 months and 11 months. At the same time, in total, the woman took several Bria-OTS courses.

It is noted that personalized cancer treatment allows targeted action on the tumor, which increases efficiency and reduces the number of side effects. The new method has the potential to treat many types of malignancies, especially those that are resistant to existing therapies.^[1]

Notes